Clinical Case Discussion with PKD Experts
This session will provide 4-6 challenging clinical case (selected in advance to be provided by Drs. Chapman, Pei, Torres and the audience) in management of patients with ADPKD. The case presentations will cover management of (i) occult infection, (ii) difficult blood pressure control, (iii) liver toxicity on AVP V2R treatment, and (iv) intracranial aneurysm screening, and two additional cases to be provided by the audience. These case presentations will be interactive, with audience polling quizzes at different stages of the presentation, followed by panel expert comments at the end.
Speakers:
York Pei MD, FRCP(C), FACPProfessor of Medicine, University of Toronto
Nephrologist, Toronto General Hospital, University Health Network
Toronto, ON
Dr. Pei is a Professor of Medicine at the University of Toronto. He is also a staff nephrologist at the Toronto General Hospital, University Health Network, where he directs the Center for Innovative Management for Polycystic Kidney Disease (https://www.cimpkd.ca/our-team.html). He received research training in both Clinical Epidemiology and Human Molecular Genetics. His research program focuses on genetic, genomic, and translational research of hereditary kidney diseases with a major focus on autosomal dominant polycystic kidney disease and is supported by grants from the Kidney Foundation of Canada, Physicians Incorporated Foundation, Polycystic Kidney Disease Foundation (USA), and Canadian Institutes of Health Research. He has published more than 150 peer-reviewed papers and had had served in the Editorial Board for the Journal of American Society of Nephrology and Grant Review Panels for the Kidney Foundation of Canada, Canadian Institutes of Health Research, PKD foundation (USA), and National Institutes of Health, USA. He was a co-recipient of the 2019 Lillian J. Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease (https://www.theisn.org/about-isn/awards-a-prizes/lillian-jean-kaplan-international-prize).
Arlene Chapman MD
Professor of Medicine, Department of Medicine, University of Chicago
Section Chief, Nephrology, Department of Medicine, University of Chicago
Director of Clinical Resource Center, University of Chicago,
Chicago, IL
I have been involved in clinical and translational research in autosomal dominant polycystic kidney disease as well as training training high school, pre med, medical students, medical residents and fellows for over 25 years. From working in the area renal physiology in pregnancy, and hypertension in ADPKD at the University of Colorado with the ADPKD Program Project Grant, to directing the PKD Foundation Cohort study which continues today, to developing and leading the CRISP Consortium and the HALT PKD A and B clinical trials as well as the TEMPO 3:4 clinical trial involving tolvaptan therapy in ADPKD I have extensive experience in clinical investigation and clinical trials in nephrology. Over the past 13 years, I have directed Clinical Research Centers at both Emory University and the University of Chicago where medical students, residents and fellows learn how to conduct clinical research across disciplines with a variety of multidisciplinary approaches. At the University of Chicago, we have been fortunate to be supported by the American Society of Nephrology (ASN), the Biological Sciences Division (BSD) and the Department of Medicine Hospitalist services to provide 2 week to 3 month extensive immersive experiences for high school, undergraduate, as well as medical and predoctoral students in the field of nephrology and renal physiology. As section chief of Nephrology at University of Chicago, I am dedicated to the training and development of our next generation of physician scientists.
Vicente E. Torres MD, PhDConsultant, Division of Nephrology & Hypertension, Department of Internal Medicine
Rochester, MN
I received MD and Doctoral degrees from the University of Barcelona and moved to the Mayo Clinic in 1972 for research training and residencies in Internal Medicine and Nephrology. During my training, I worked on the role of prostaglandins in acute renal failure (in Dr. Cameron G. Strong’s laboratory) and on the distribution and modulation of cyclic nucleotide phosphodiesterases in the kidney (in Dr. Thomas P. Dousa’s laboratory). I joined the faculty of the Mayo Clinic in 1979 and became Professor of Medicine in 1991. After working in the areas of primary glomerulopathies, reflux nephropathy and renal transplantation, I became increasingly interested in polycystic kidney disease (PKD) and related diseases and these have been the focus of my research for the last three decades. I have published extensively on topics ranging from epidemiology, phenotypic characterization, natural history and clinical management of these diseases to identification of responsible genes, expression and function of the encoded proteins, and preclinical and clinical therapeutic trials. Translational studies and attempts to improve treatment options for ADPKD have been my major focus. I am a PI for the NIH-funded CRISP imaging study and the recently completed HALT-PKD clinical trial and for the Industry-funded clinical trials of vasopressin V2 receptor antagonists, and the Director of the NIH-funded Mayo Translational PKD Center. My contributions to PKD research were recognized by the 2007 Lillian Jean Kaplan International Prize for Advancement in the Understanding of PKD and the 2019 John P. Peters Award of the American Society of Nephrology. In addition, I have served as Chair of the Division of Nephrology and Hypertension at the Mayo Clinic, Director of the NIH-funded Mayo Kidney Disease Research Training Grant, and on the Scientific Advisory Board of the PKD Foundation and several editorial boards and NIH study sections and committees. I have organized a number of meetings on PKD, most recently the first Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference dedicated to PKD and the 2017 FASEB Science Research Conference on PKD.